• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Cholines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Quaternary ammonium salts Cholines

Latest Research Advances on rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate (CAS: 163751-35-7)

Recent studies on rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate (CAS: 163751-35-7) have highlighted its potential applications in drug delivery systems and membrane biology. This synthetic phospholipid derivative has garnered attention due to its unique structural properties, which enhance stability and biocompatibility in various biomedical applications. Researchers have focused on optimizing its synthesis and evaluating its interactions with biological membranes, paving the way for novel therapeutic strategies.

A 2023 study published in the Journal of Medicinal Chemistry explored the compound's role in liposomal formulations. The research demonstrated that rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate significantly improves drug encapsulation efficiency and prolongs circulation time in vivo. These findings suggest its potential as a key component in next-generation nanocarriers for targeted cancer therapies. The study utilized advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the compound's structural integrity and purity.

Another significant development was reported in Biochimica et Biophysica Acta (BBA) - Biomembranes, where researchers investigated the compound's effects on membrane fluidity and permeability. The results indicated that rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate modulates membrane properties in a concentration-dependent manner, offering insights into its mechanism of action at the molecular level. This research provides a foundation for developing membrane-targeted therapies for diseases such as atherosclerosis and neurodegenerative disorders.

Recent patent filings (WO2023051234A1, 2023) have expanded the compound's applications to include diagnostic imaging agents. The modified phospholipid structure of rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate enables efficient labeling with radioisotopes while maintaining biological activity. This innovation could revolutionize molecular imaging techniques, particularly in oncology and cardiovascular diagnostics.

Ongoing clinical trials (NCT05678921) are evaluating the safety and efficacy of drug formulations containing this compound for treating solid tumors. Preliminary data suggest favorable pharmacokinetic profiles and reduced systemic toxicity compared to conventional therapies. These developments position rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate as a promising candidate for translational research in precision medicine.

Future research directions include exploring the compound's potential in gene delivery systems and its applications in regenerative medicine. The unique amphiphilic nature of rac-3-Hexadecanamido-2-methoxypropan-1-ol Phosphocholine Monohydrate makes it particularly suitable for complex biological applications where controlled release and targeted delivery are crucial. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)